
Food sold at Target is recalled due to elevated lead levels
A company that makes baby food sold under a Target store brand is recalling more than 25,000 packages of a product because the food may contain elevated levels of lead.
Miami-based Fruselva issued the recall in March for Target's Good & Gather Baby Pea, Zucchini, Kale & Thyme Vegetable Purée, sold in 4-ounce tubs, according to the U.S. Food and Drug Administration (FDA).
The packages include lot number 4167, with a best-by date of Dec. 7, and lot number 4169, with a best-by date of Dec. 9.
Consumers should not feed these products to babies, the notice indicates.
A Target spokesperson told Fox News Digital the recall "involved a limited amount of product, which we took immediate action to remove from our shelves."
Because the recall was initiated in March, no impacted products are in circulation, the spokesperson said.
The recall is listed as Class II, which means the products are unlikely to cause serious harm but still have the potential to result in temporary or reversible problems.
For more Lifestyle articles, visit foxnews.com/lifestyle
There is no safe level of exposure to lead for children, according to the U.S. Centers for Disease Control and Prevention (CDC).
Exposure to the heavy metal can cause developmental and cognitive problems.
"As the lead levels rise, children may complain of non-specific symptoms such as headaches, abdominal pain, loss of appetite or constipation," according to the American Academy of Pediatrics.
"Children with signs of clumsiness, agitation or decreased activity and drowsiness may be showing signs of central nervous system (CNS) involvement that may rapidly proceed to vomiting, stupor and convulsions. Symptomatic lead toxicity must be treated as an emergency."
Most baby food in the U.S. can contain no more than 10 parts per billion of lead — while root vegetable baby food and dry cereals are allowed 20 parts per billion, according to FDA standards listed on its website.
Anyone who has the recalled baby food is asked to call corporate guest relations or go to a Target store for a full refund.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
17 minutes ago
- Bloomberg
Millions of Eggs Recalled After Dozens Sickened With Salmonella
The US Food and Drug Administration said more than 20 million eggs have been recalled after 21 people were hospitalized with salmonella. The eggs, distributed by the August Egg Company, were sold to retailers including Walmart Inc. and Safeway Stores Inc. between February 3 and May 19. The sell-by dates ranged from March 4 to June 19, the FDA said with its full list of brands involved.
Yahoo
19 minutes ago
- Yahoo
Gilbane, F.A. Wilhelm top out $4.3B Indianapolis hospital
This story was originally published on Construction Dive. To receive daily news and insights, subscribe to our free daily Construction Dive newsletter. A joint venture of Providence, Rhode Island-based Gilbane Building Co. and Indianapolis-based F.A. Wilhelm topped out Indiana University Health's new downtown Indianapolis hospital, according to a May 27 Gilbane news release. The $4.3 billion, 2.1 million-square-foot hospital, announced in August 2020, will contain 864 inpatient rooms, 50 operating rooms and two helipads, according to Gilbane's project page. It will combine the health system's Methodist and University Hospitals, and is on track to finish in 2027, according to a June 2024 construction update. The medical project, initially budgeted at $1.6 billion, swelled to $4.3 billion in 2023. Growing construction costs of more than 20% of the initial budget and a height increase in the hospital's three bed towers to 16 stories initially increased it to $2.31 billion, according to a 2023 news release from the hospital network. Along with those construction costs, support buildings and other infrastructure — which include medical offices, parking garages and logistics space — tacked on an additional $1.98 billion to the project's price tag, per the news release. Combined, the inflated costs and additional work more than doubled the original budget. The hospital will also feature three clinical institutes for cancer, cardiovascular and neuroscience care, according to the hospital's project page. The complex will include bridges to the Capitol View medical office building, the Indiana University School of Medicine and the South Support Building, per Gilbane. At a lower level, below-grade tunnels will traverse from the hospital to the School of Medicine, South Support Building and central utility plant. 'Reaching the topping-out milestone is a proud moment for our entire team,' said Aaron Perry, Gilbane's project director, in the release. 'It reflects years of hard work, coordination, and a shared dedication to safety and quality.' Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. Related L'Oréal acquires Galderma stake and targets the injectables market The Body Shop goes into administration, with hundreds of UK jobs at risk This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data